What will make it an Overwhelming QbD Conference?

Dear Colleagues,

Many of you wonderful scientists must be having one or more of the following questions in your mind.

What is different in this QbD conference?

I have attended so many QbD conferences, why one more??

QbD is same always, what is new in this conference???

I am from XYZ department, will I gain anything????

I am busy, how should I take out time for this conference?????

However, we wish to tell you that our “QbD in Pharma Developement World Congress 2015 ” is going to be a great conference.  We have done efforts to make this conference the best possible with several happenings which have never been collectively there before at any QbD conference viz Problem Solving Software Training and discussion on the following and many more topics.

  • Question based Review and Continued Process Verification
  • Question based Approach to Product Development
  • Integration of Quality by Design from Product Development to API Production
  • Methods to Minimize the Impact of Uncertainty in Pharma Quality Attributes
  • Realization of Quality by Design in ANDA Submissions
  • How to Demonstrate the Relevant Diligence on Filing
  • Risk Based Approach for Efficient Development of the DS Control Strategy
  • QbD & QbR to Reduce Health Care Cost while Maintaining Quality
  • How to find the Robust Setpoint for Design Space Combining DOE Models, Monte Carlo Simulations and Design Space Concept
  • ATP and CQA For Analytical Methods
  • Risk Assessment In Aqbd and Design Space for Analytical Methods
  • Tools that Play a Critical Role in Implementation of Qbd for Biotech Processes
  • Five-D Concept of QbD
  • Live Demonstration on How to Utilize Tools of Qbd i.e. DoE & PAT
  • Industry Case-Studies Related to Implementation of PAT
  • How To Implement DoE & PAT Systematically & Effectively during Development & Manufacturing of Solid Oral/Liquid Orals/ Semisolids & Parenteral Dosage Forms
  • DoE for Development of a Modified-Release Tablet
  • Advanced DoE for Improved Process Understanding
  • Statistics in Product Development – Beyond DoE
  • Use of other Statistical Tools to Build Robust Products & Processes
  • Chemometric Tools in QbD -Chemometric Methods & their Advantages and Principle
  • QbD Based Systematic Development of Nanoemulsions for Natural Product
  • Analytical Quality By Design (Aqbd) Approach In RP-HPLC Method Development
  • Quality By Design (QbD) Approach in Formulation of Oral Delayed Release Tablet of LansoprazolFor details, please find attached the agenda of the conference. Looking into the above topics being covered, we feel that we have the answers to the above questions
  •  You were looking for the best QbD scientists and there they are.
  • This is not like the earlier conferences since the quality of talks is exceptionally high and specifically meant to enhance your process and product understanding.
  • QbD has to be implemented holistically and if you are a scientist from Quality assurance, Analytical development, API Development or Formulation Development, it is relevant for you.
  • You are entrusted with responsibility to develop products and processes of high quality for effective ANDA filings and that exactly the aim of this conference is.
  • You spend lot of time in sorting out QbD data related problems which your colleagues must be facing. Be there, get your data problems solved and save time.
  • Finally get tips on how to develop medicine in cost effective manner and give your company a return which is much higher than investment in this conference.

So what are you waiting for? Register now

Our worthy Speakers and we all will be doing our best and Now it is your presence which will make it an Awesome Conference.!!!

Looking forward to see you in Chandigarh.

How to develop Smaller and Cheaper Cell-Based Assays for HCA?

Assay Miniaturization Strategies:  Smaller and Cheaper Cell-Based Assays for HCA

Learn from Dr Anthony Davies, Director, TCIQ, Queensland, Australia at CellTech India 2015 in Bangalore on March 2-3, 2015.

Abstract

To sustain the viability of large-scale research programs running in academia and industry (especially when considering the current global economic climate), it is essential to reduce research costs wherever possible.  With the advent of micron resolution robotics and nano-litre capable liquid handlers, assay miniaturization for large-scale High-Content Screening is now possible. The advantages of miniaturization are clear, when one considers the savings in reagents and experimental materials and experimental turnaround times.  However miniaturization can also be costly to set up and difficult to deploy.

Cell Tech India 2015-2 698x400

How to choose right tool to implement 3D Cell-based Assays?

 The Implementation of 3D Cell based Assays and High Content Imaging in Translational Research: Choosing the right tools for the Job

High Content Screening and analysis (HCS/A) technologies have over the last 15 years become widely adopted in both the academic and industrial research sectors. The acceptance of these technologies has in the large part been due to their demonstrable utility as both drug-discovery and basic research tools, indeed these imaging technologies such as HCS/A have the capability of providing researchers with a ready means of performing both large scale primary screens as well as permitting more detailed downstream analysis.  Alongside the rapid uptake of these technologies, we have also seen a concomitant increase in the demand for more refined and flexible hardware and biologically relevant cell based assay approaches that can be utilized for translational research.  Currently one of the biggest drivers in the field is the need to improve the physiological relevance of cell based assays used within translational research campaigns. To achieve these aims many are turning their attention to the use of primary cells and/or 3 dimensional cellular assay models. In summary this presentation will cover the key technological and methodological approaches we are currently implementing within our High Content Analysis workflows to meet our translational research goals. This talk will be presented at CellTech India 2015 in Bangalore on March 2, 2015 by Dr. Anthony Mitchell Davies, Queensland, Australia. Dr. Anthony Mitchell Davies is currently the Center Director: Translational Cell Imaging, Institute of Health Biomedical Innovation, Australia

Cell Tech India 2015-2 920x270 RGB jpgTraining Course 2014 Celltech 920x270 RGB